Promising Pharmaceutical Stocks Worth Watching - November 20th

Eli Lilly and Company logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • MarketBeat identified seven pharmaceutical stocks to watch based on recent dollar trading volume: Eli Lilly, Johnson & Johnson, Merck, AbbVie, Insmed, Pfizer, and Gilead Sciences.
  • The companies cover a range of drug markets, including diabetes and obesity treatments at Lilly, oncology and immunology medicines at AbbVie and Merck, and HIV therapies at Gilead.
  • Most of the stocks rose in Friday midday trading; AbbVie gained $4.79 and Gilead $1.96, while Pfizer slipped by $0.01.
  • MarketBeat previews top five stocks to own in December.

Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc., AbbVie, Insmed, Pfizer, and Gilead Sciences are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares in companies that develop, manufacture, or market prescription and over-the-counter medicines. For investors, their value can be affected by factors such as clinical-trial results, regulatory approvals, patent protection, and drug sales. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Shares of NYSE LLY traded up $1.34 during midday trading on Friday, reaching $1,352.46. 1,388,315 shares of the company's stock were exchanged, compared to its average volume of 2,950,835. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. Eli Lilly and Company has a 52-week low of $850.51 and a 52-week high of $1,475.25. The business's fifty day moving average price is $1,263.45 and its two-hundred day moving average price is $1,117.53. The stock has a market capitalization of $1.27 trillion, a PE ratio of 43.87, a price-to-earnings-growth ratio of 1.65 and a beta of 0.40.

Read Our Latest Research Report on LLY

Johnson & Johnson (JNJ)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

NYSE JNJ traded up $3.39 during mid-day trading on Friday, reaching $270.53. 3,749,165 shares of the company's stock traded hands, compared to its average volume of 7,946,023. Johnson & Johnson has a 1-year low of $199.90 and a 1-year high of $290.25. The company has a fifty day simple moving average of $267.43 and a 200-day simple moving average of $250.79. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. The company has a market cap of $651.26 billion, a price-to-earnings ratio of 40.99, a P/E/G ratio of 2.74 and a beta of 0.22.

Read Our Latest Research Report on JNJ

Merck & Co., Inc. (MRK)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Shares of MRK traded up $1.72 during midday trading on Friday, hitting $134.53. The company had a trading volume of 5,976,750 shares, compared to its average volume of 10,519,341. The company's 50 day moving average price is $145.49 and its 200 day moving average price is $129.20. Merck & Co., Inc. has a 52 week low of $95.36 and a 52 week high of $156.92. The stock has a market cap of $331.64 billion, a price-to-earnings ratio of 138.74, a PEG ratio of 6.32 and a beta of 0.13. The company has a quick ratio of 1.14, a current ratio of 1.35 and a debt-to-equity ratio of 1.11.

Read Our Latest Research Report on MRK

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of NYSE ABBV traded up $4.79 during midday trading on Friday, hitting $288.33. The company's stock had a trading volume of 2,266,979 shares, compared to its average volume of 6,253,592. The firm's fifty day moving average price is $278.40 and its 200-day moving average price is $242.25. AbbVie has a 1-year low of $190.75 and a 1-year high of $302.93. The firm has a market cap of $509.67 billion, a P/E ratio of 49.65, a P/E/G ratio of 1.30 and a beta of 0.20.

Read Our Latest Research Report on ABBV

Insmed (INSM)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Insmed stock traded up $0.23 during midday trading on Friday, reaching $144.69. 2,838,949 shares of the stock traded hands, compared to its average volume of 3,044,856. Insmed has a fifty-two week low of $90.39 and a fifty-two week high of $212.75. The firm has a market cap of $31.74 billion, a price-to-earnings ratio of -51.35 and a beta of 0.83. The firm has a fifty day moving average price of $110.85 and a two-hundred day moving average price of $122.79. The company has a current ratio of 2.86, a quick ratio of 2.59 and a debt-to-equity ratio of 0.77.

Read Our Latest Research Report on INSM

Pfizer (PFE)

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Shares of PFE traded down $0.01 during trading hours on Friday, reaching $27.52. 14,168,594 shares of the company's stock traded hands, compared to its average volume of 39,568,797. Pfizer has a twelve month low of $23.62 and a twelve month high of $31.44. The business's fifty day simple moving average is $28.83 and its two-hundred day simple moving average is $27.02. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.42 and a quick ratio of 1.10. The firm has a market capitalization of $156.89 billion, a price-to-earnings ratio of 39.31, a P/E/G ratio of 1.84 and a beta of 0.31.

Read Our Latest Research Report on PFE

Gilead Sciences (GILD)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Shares of NASDAQ GILD traded up $1.96 during mid-day trading on Friday, reaching $168.49. 2,121,427 shares of the company traded hands, compared to its average volume of 6,750,926. The firm has a market cap of $208.98 billion, a PE ratio of -53.26 and a beta of 0.35. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 1.22. Gilead Sciences has a fifty-two week low of $116.88 and a fifty-two week high of $176.58. The stock has a fifty day simple moving average of $156.80 and a 200-day simple moving average of $142.34.

Read Our Latest Research Report on GILD

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Eli Lilly and Company Right Now?

Before you consider Eli Lilly and Company, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.

While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Related Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines